Scholarlink

<p>Biocomposite implants for osteomyelitis treatment were developed by impregnation of bovine spongy bone with medicinal polysaccharide gels. This gel comprises dialdehyde carboxymethylcellulose (DACMC), containing covalently bound vancomycin to provide implants with antibacterial properties, as well as an intracellular drug delivery system based on a hyaluronic acid (HA) nano-emulsion carrying the nonsteroidal anti-inflammatory drug (NSAID) tenoxicam for control of local aseptic inflammation. The structure of the polymers and the binding sites of vancomycin molecules to the carrier’s main chain were determined using matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and <sup>13</sup>C nuclear magnetic resonance (NMR) spectroscopy. The size of the hyaluronic acid droplets containing tenoxicam was determined using dynamic light scattering (DLS) as well as by scanning electron microscopy (SEM). Cytotoxic properties of the dry gels, as well as the minimum inhibitory concentration and minimum bactericidal concentration against <i>Staphylococcus aureus 209P</i> were determined by respective in vitro studies. The efficacy of biocomposite implants was tested using in vivo experiments followed by histological analysis. These biocomposites show promise for the treatment of osteomyelitis.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biocomposite materials with polysaccharide coating containing covalently bound vancomycin, tenoxicam and hyaluronic acid nanoemulsion in the treatment of rat experimental osteomyelitis

  • 期刊论文

  • 发表日期：

    2026年4月16日

查看全文
  • Valerie Dyatlov,
  • Eva Kostandyan,
  • Viktoria Mendrul,
  • Tatiana Seregina,
  • Sergey Tsirulnikov,
  • Anatoliy Suslov,
  • Anna Vaniushenkova,
  • Efrem Krivoborodov,
  • Marchel Vetrila,
  • Ilya Shelomentsev,
  • Alexander Dyatlov

摘要

Biocomposite implants for osteomyelitis treatment were developed by impregnation of bovine spongy bone with medicinal polysaccharide gels. This gel comprises dialdehyde carboxymethylcellulose (DACMC), containing covalently bound vancomycin to provide implants with antibacterial properties, as well as an intracellular drug delivery system based on a hyaluronic acid (HA) nano-emulsion carrying the nonsteroidal anti-inflammatory drug (NSAID) tenoxicam for control of local aseptic inflammation. The structure of the polymers and the binding sites of vancomycin molecules to the carrier’s main chain were determined using matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 13C nuclear magnetic resonance (NMR) spectroscopy. The size of the hyaluronic acid droplets containing tenoxicam was determined using dynamic light scattering (DLS) as well as by scanning electron microscopy (SEM). Cytotoxic properties of the dry gels, as well as the minimum inhibitory concentration and minimum bactericidal concentration against Staphylococcus aureus 209P were determined by respective in vitro studies. The efficacy of biocomposite implants was tested using in vivo experiments followed by histological analysis. These biocomposites show promise for the treatment of osteomyelitis.

Graphical abstract